ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER

Clinical trials for ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER trials appear

Sign up with your email to follow new studies for ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope: early access to promising breast cancer drug giredestrant

Disease control AVAILABLE

This program offers early access to giredestrant for people with ER-positive, HER2-negative breast cancer that is either early stage or has spread. Participants must have confirmed ER+ and HER2- tumors. The goal is to provide treatment before the drug is widely available in the U…

Matched conditions: ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER

Sponsor: Genentech, Inc. • Aim: Disease control

Last updated Jun 17, 2026 12:04 UTC

ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER

Get alerted when new ER+/HER2- EARLY OR LOCALLY ADVANCED/METASTATIC BREAST CANCER trials appear

New hope: early access to promising breast cancer drug giredestrant